RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 – ResearchAndMarkets.com

The global RNA Vaccines and RNA Therapeutics market is projected to experience substantial growth, with an estimated worth of over USD 1.1 billion by 2035 and a compounded annual growth rate (CAGR) of 50% during the forecast period from 2026 to 2035.

RNA-based therapeutics have gained prominence in the healthcare industry due to their potential in protein production and gene function regulation, offering advantages in terms of therapeutic efficacy and safety compared to traditional treatment approaches.

Key Highlights and Trends:

1. Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable. These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA). These therapies offer structural stability, expression specificity, targeted delivery, non-immunogenicity, high efficiency, and the ability to target a wide range of therapeutic areas.
2. Clinical Trials: Over 100 next-generation RNA therapeutics and RNA vaccines are currently approved or in various stages of development, with nearly 25% in clinical trials. A significant portion of these candidates focuses on infectious diseases (40%) and oncological disorders (32%). High research efforts and clinical trials in this domain indicate substantial growth potential.
3. Self-Amplifying mRNA Vaccines: Self-amplifying mRNA (saRNA) vaccines have gained attention, with advantages over first-generation mRNA vaccines. These saRNA vaccines offer enhanced stability, low concentration administration, and prolonged therapeutic effects, making them a potential alternative to traditional RNA-based approaches.
4. tRNA Therapeutics: Transfer RNA (tRNA) therapies are being explored by companies like Alltrna and ReCode Therapeutics. These therapies involve engineering tRNA to correct gene codes and regulate gene expression. Although still in early stages of development, these therapies hold promise for conditions such as Cystic Fibrosis, Duchenne Muscular Dystrophy, and Pulmonary Sarcoidosis.
5. Circular RNA Therapeutics: Circular RNA therapies have attracted interest due to their stability. Start-ups and funding activity in this field have surged, with companies like Chimerna Therapeutics, Esperovax, and Orna Therapeutics making significant strides. Collaborations and partnerships are driving the development of circular RNA therapies.
6. North America Dominance: North America leads the market, with approximately 94% of the market share projected for 2035. However, Asia-Pacific is expected to experience faster growth during the forecast period.
7. Stakeholder Engagement: Many companies are partnering to advance research and development in next-generation RNA therapeutics and vaccines. Several strategic partnerships have been established, with over 22% focused on research and development agreements.
8. Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019. This indicates strong interest and financial support from stakeholders.
9. Recent Developments: Notable recent developments include collaborations between Tevard Biosciences and Vertex Pharmaceuticals for tRNA therapies, Esperovax and Gingko Bioworks for circular RNA therapeutics, and HDT Bio’s technology utilization agreement with the Pan African Cancer Research Institute (PACRI) for self-amplifying RNA vaccines and therapeutics.